Nanobodies are single domain antibodies derived from llama heavy-chain only antibodies (HCAbs)
The discovery of nanobodies by Raymond Hamers in the 1980s and the further development of the technology by Serge Muyldermans and Jan Steyaert fundamentally changed approaches in different areas of medicine. Nanobodies are very useful in the diagnosis and treatment of serious and life-threatening diseases.
As nanobodies were born at the University of Brussels, the VIB-VUB Center for Structural Biology is very honored to organize the second edition of the Nanobody conference. This meeting series was launched in September 2019 at the University of Bonn by Florian Schmidt and Paul-Albert König.
During the 2day conference on 8-10 September 2021, leaders in the field will present their latest findings in sessions focused on:
- Nanobody fundamentals
- Nanobody engineering
- Innovative research tools
- Nanobodies in diagnostics, imaging and microscopy
- Nanobodies in target validation
- Nanobodies as therapeutic molecules
- Nanobodies as anti-infectious agents
On Friday 10 September, a satellite event ‘Nanobodies in structural biology’ will be held.
- Enrica Bordignon, Ruhr University Bochum, DE
- Martine Smit, VU, NL
- Andrew Kruse, Harvard Medical School, US
- Karine Breckpot, VUB, BE
- Mohammad Rashidian, Dana Farber Cancer Institute, US
- Miriam Stöber, University of Geneva, CH
and many more